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The development of therapeutic strategies to inhibit reac-
tive oxygen species (ROS)-mediated damage in blood vessels
has been limited by a lack of specific targets for intervention.
Targeting ROS-mediated events in the vessel wall is of inter-
est, because ROS play important roles throughout atherogen-
esis. In early atherosclerosis, ROS stimulate vascular smooth
muscle cell (VSMC) growth, whereas in late stages of lesion
development, ROS induce VSMC apoptosis, causing athero-
sclerotic plaque instability. To identify putative protective
genes against oxidative stress, mouse aortic VSMC were
infected with a retroviral human heart cDNA expression
library, and apoptosis was induced in virus-infected cells by
2,3-dimethoxy-1,4-naphthoquinone (DMNQ) treatment. A
total of 17 different, complete cDNAs were identified from
the DMNQ-resistant VSMC clones by PCR amplification and
sequencing. The cDNA encoding PP1c1 (catalytic subunit
of protein phosphatase 1) was present in several independent
DMNQ-resistant VSMC clones. DMNQ increased mitochon-
drial ROS production, caspase-3/7 activity, DNA fragmenta-
tion, and decreased mitochondrial transmembrane potential
in VSMC while decreasing PP1c1 activity and expression.
Depletion of PP1c1 expression by short hairpin RNA signif-
icantly enhanced basal as well as DMNQ-induced VSMC apo-
ptosis. PP1c1 overexpression abrogated DMNQ-induced
JNK1 activity, p53 Ser15 phosphorylation, and Bax expression
and protected VSMC against DMNQ-induced apoptosis. In
addition, PP1c1 overexpression attenuated DMNQ-in-
duced caspase-3/7 activation and DNA fragmentation. Inhi-
bition of p53 protein expression using small interfering RNA
abrogated DMNQ-induced Bax expression and significantly
attenuated VSMC apoptosis. Together, these data indicate
that PP1c1 overexpression promotes VSMC survival by
interfering with JNK1 and p53 phosphorylation cascades
involved in apoptosis.
Enhanced reactive oxygen species (ROS)3 generation plays
an important role in the proliferation, migration, or apoptosis
of vascular smoothmuscle cells (VSMC), all of which have been
implicated in the pathophysiology of vascular diseases, includ-
ing atherosclerosis. VSMC proliferation and migration are
important in the development of atherosclerotic lesions, and
VSMC apoptosis is a histologic hallmark of advanced athero-
sclerosis (1). Additionally, human VSMC isolated from coro-
nary plaques aremore susceptible to apoptosis than VSMC iso-
lated from normal arteries (2). Apoptosis of VSMC in
atherosclerotic plaques is accompanied by numerous other
events that increase the likelihood of plaque rupture. These
include decreases in collagen and extracellular matrix protein
production, decreased fibrous cap thickness, accumulation of
macrophages along the shoulder of the plaque, and increases in
the size of the necrotic core and amount of cellular debris
within the plaque (3). A better understanding of the mecha-
nisms that regulate VSMC apoptosis could lead to the develop-
ment of strategies to stabilize atherosclerotic plaques.
Identifying genes that could protect cells against oxidative
stress requires selection of an oxidant and a screening strategy.
A number of different approaches have been used to induce
oxidative stress in cultured cells and in vivo. The quinones are
of particular interest. Quinones are ubiquitous in nature and
are also formed as metabolites from a variety of drugs, environ-
mental pollutants, and food derivatives by the action of cyto-
chromeP450 system (4). The redox-cycling 2,3-dimethoxy-1,4-
naphthoquinone (DMNQ) has been proposed as a model
quinone compound to study the role of ROS in cell toxicity and
apoptosis (5). It does not react with free thiol groups and is
nonalkylating and nonadduct-forming. One-electron reduc-
tion of DMNQ by flavoenzymes, such as NADPH-cytochrome
P450 reductase or NADH-cytochrome b5 reductase, yields a
semiquinone radical, which then reacts with oxygen to form
superoxide (O2. ) and, subsequently, the dismutation product
H2O2. An obligatory two-electron reducing cytosolic flavoen-
zymeNADPHoxidoreductase 1, also known asDT-diaphorase,
can compete with one-electron reductases for DMNQ to pro-
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duce a hydroquinone, which can undergo autoxidation to yield
H2O2 and the parental quinone.
Retroviral cDNA expression library screening has been used
successfully to identify novel oncogenes (6) and modulators of
apoptosis (7, 8). The packaging cell lines used in conjunction
with retroviral vectors generate high concentrations of infec-
tious virus particles necessary for the efficient infection of large
cell populations, including that of primary cells, with a single
copy of vector per cell (9). In addition, retroviral delivery sys-
tems have the ability to deliver very large libraries to infected
cell populations. These properties make retroviral cDNA
expression library screening an ideal strategy to identify genes
that protect against oxidative stress.
Protein phosphorylation and dephosphorylation play an
important regulatory role in apoptosis and other cellular pro-
cesses (10–12). Protein phosphatase 1 (PP1), 2A (PP2A), 2B
(PP2B), and 2C (PP2C) are the four major serine/threonine
phosphatases present in eukaryotic cells (13).Of these four, PP1
and PP2A account for the majority of cellular phosphatase
activity (13). The catalytic subunit of PP1 exists in four different
isoforms (, 1, 2, and ), which are targeted to various sub-
cellular compartments by association with distinct regulatory
proteins (14, 15). The interaction of targeting proteins with the
catalytic subunit also modulates substrate specificity, enabling
unique and independent roles for the various isoforms in regu-
lating discrete cellular processes (15).
Okadaic acid, a potent inhibitor of PP1 and PP2A, induces
apoptosis in several cells, and this was attributed to its prefer-
ential inhibition of one or the other isoform depending on the
cell type (16–19). Okadaic acid-induced epithelial cell apopto-
sis and inhibition of PP1were correlatedwith increased expres-
sion of tumor suppressor gene p53 and proapoptotic gene Bax
(19). Serine phosphorylation in both the carboxyl-terminal and
N-terminal domains modulates DNA binding ability and tran-
scriptional activity of p53 (20, 21). It has been shown recently
that direct dephosphorylation of p53 at Ser15 and Ser37 by PP1
affects its stability and transcriptional and apoptotic activities
(22, 23).
Among the kinases that regulate the p53 pathway are the
c-Jun NH2-terminal kinase (JNK) group of mitogen-activated
protein kinases. JNKs are activated in cells exposed to various
environmental stresses (24), and reactive oxygen species (ROS)
play an integral part in this activation (25). The 10 members of
the JNK family are generated by alternative splicing of tran-
scripts from Jnk1, Jnk2, and Jnk3 genes (24). Jnk1 and Jnk2 dou-
ble knock-out cells are resistant to apoptosis induced by UV,
anisomycin, or DNA damage (26). Proapoptotic proteins Bax
and Bak are necessary for JNK-induced apoptosis, and Bax
remains inactive in Jnk-deficient fibroblasts exposed to envi-
ronmental stress (27). JNK is activated by dual phosphorylation
at Thr183 and Tyr185 residues (24), which are dephosphorylated
by dual specificity mitogen-activated protein kinase phospha-
tases (28).
In this study, we used retrovirus-mediated insertion of a
human heart cDNA library into mouse aortic VSMC to create
DMNQ-resistant cell clones. The clones contained 17 full-
length cDNAs.We chose to investigate the role of PP1c1 (cat-
alytic subunit of protein phosphatase 1) in oxidative stress
resistance because the cDNA coding for this protein was pres-
ent in several independent DMNQ-resistant VSMC clones and
because of our continued interest in protein phosphorylation as
a regulatory mechanism in atherosclerotic disease process in
general and VSMC biology in particular. DMNQ treatment
inducedmitochondrial ROS production and decreased PP1c1
activity in VSMC. Overexpression of PP1c1 decreased
DMNQ-induced phosphorylation of JNK1 and p53 (Ser15) and
protected against DMNQ-induced apoptosis. Further, p53
shRNA transfection protected VSMC against DMNQ-induced
apoptosis. Together, these results suggest that PP1c1may reg-
ulate molecular mechanisms that mediate VSMC apoptosis in
atherosclerosis and restenosis.
EXPERIMENTAL PROCEDURES
Materials—DMNQ and diphenyleneiodonium chloride
(DPI) were obtained from Calbiochem. Rotenone, thenoyltrif-
luoroacetone, carbonyl cyanide m-chlorophenylhydrazone,
oxypurinol, proadifen, phenelzine, indomethacin, nordihydro-
guaiaretic acid, leptin, and antimycin A were purchased from
Sigma. MitoTracker Green FM, MitoSOX Red, and 2,7-di-
chlorofluorescein diacetate were purchased from Molecular
Probes (Invitrogen). The antibodies used were anti-PP1c1,
anti-p53, anti-Bax, and anti-JNK1 (Santa Cruz Biotechnology),
anti-phospho-p53 (Ser15) (Cell SignalingTechnology), andanti--
actin (Sigma).Glutathione S-transferase-c-Jun-(1–79) recombi-
nant protein was obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). [-32P]ATP (6,000 Ci/mmol) was obtained
from GE Healthcare.
Cell Culture—Aortic VSMCwere isolated from4-month-old
male C57BL/6 mice as previously described by us (29). Cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% (v/v) fetal bovine serum (FBS) as
described previously (30). All experiments were conducted
using VSMC between passages 4 and 11 that were growth-ar-
rested by incubation in DMEM containing 0.1% FBS for 72 h.
Quiesced VSMC were treated with 60 M DMNQ for 16 h.
Single cell clones that survived the treatment were isolated by
localized trypsinization using cloning cylinders (Sigma) and
expanded using the Glasgow modification of Eagle’s medium
supplemented with 2 mM glutamine, 1 mM sodium pyruvate,
1 nonessential amino acids, 10% (v/v) fetal bovine serum, a
1:1000 dilution of -mercaptoethanol stock solution (70 l of
-mercaptoethanol in 20 ml of distilled water), and 500
units/ml of leukocyte-inhibitory factor (Chemicon).
Virus Production—A human heart cDNA expression library
was constructed in a replication-defectiveMoloneymurine leu-
kemia virus-based vector, pCFB (Stratagene). The unidirec-
tionally oriented cDNA library contained 1  106 primary
clones andwas amplified only once to ensure the best represen-
tation. Retrovirus was produced using the MBS mammalian
transfection kit (Stratagene). In brief, the ecotropic virus pack-
aging cell line Phoenix-Eco (Orbigen) was transfected with
pCFB-human heart cDNA expression library or retroviral plas-
mid by the calcium phosphate-DNA co-precipitation method.
Retroviruses secreted by transfected cells were collected from
cell supernatant 24, 48, and 72 h after transfection and imme-
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diately applied to VSMCor 293T cells without any freezing and
thawing steps.
The concentration of infectious particles was determined by
exposing 293T cells to virus containing the lacZ reporter gene
(pFB-Neo-LacZ; Stratagene). In brief, cells were seeded at a
density of 2.5  105 cells/well in a 6-well plate, 16 h prior to
virus infection. Infection/transduction was performed in the
presence of 10 g/ml DEAE-dextran. After 24 h of incubation
at 37 °C, cells were stained for -galactosidase expression using
an in situ-galactosidase staining kit (Stratagene). The number
of blue-stained cells was estimated by lightmicroscopy at200
magnification.
cDNA Library Screening in VSMC—VSMC (1.0  106) were
seeded in 15-cm tissue culture dishes. Ten dishes (about 1 
107 cells) were infected with 2  106 infectious particles of
human heart cDNA expression library in pCFB retrovirus as
described above. 20% infection was achieved as determined by
staining for -galactosidase activity in control cells.
Infected cells were incubated for 48 h at 37 °C to achieve
maximal expression of genes (ViraPort XR Plasmid cDNA
Library protocol; Stratagene). Then VSMC were treated with
60 MDMNQ for 16 h. Single cell clones that survived DMNQ
treatment were isolated as described above.
Isolation and Sequencing of Transduced cDNAs—Genomic
DNA from 132 clones was isolated using the DNeasy tissue kit
(Qiagen) and was used for PCR recovery of cDNA inserts. A 5
Retro primer (5-GGCTGCCGACCCCGGGGGTGG-3) and
3 Retro primer (5-CGAACCCCAGAGTCCCGCTCA-3)
specific for the virus vector sequence flanking cDNA inserts
were used for PCR synthesis of cDNAs. PCR was run for 33
cycles (15 s at 94 °C, 4 min at 68 °C) and a final extension for 10
min at 72 °C. The PCR products were purified using the
QIAquick PCR purification kit (Qiagen) and sequenced using
the above mentioned primers. The PCR products were ana-
lyzed on agarose gels to determine the length of the cDNAs.
Construction of Recombinant Viruses—To make retroviral
and adenoviral constructs encoding PP1c1 cDNA, PP1c1
was subcloned from pEGFP-C1-PP1c1 (kindly provided by
Dr. Laura Trinkle-Mulcahy (University of Dundee, Scotland))
into pQCXIP (BD Bioscienses) and pShuttle-CMV, respec-
tively. The sequence of PP1c1 constructs was confirmed by
restriction analysis and DNA sequencing. Retrovirus encoding
PP1c1 cDNA was generated as described above. Adenovirus
encoding PP1c1 cDNA was generated after homologous
recombination of pShuttle-CMV containing PP1c1 cDNA
with the adenoviral backbone plasmid pADEasy-1 in BJ5183
Escherichia coli (Stratagene). The recombinant (LE1/E3-defi-
cient) adenoviruses were propagated by the transfection of
human embryonic kidney 293 cells using Lipofectamine
(Invitrogen). The virus was serially amplified and then purified
using the ViraBind adenovirus purification kit (Cell Biolabs,
Inc.). A control adenovirus contained an identical adenovirus
backbone with green fluorescent protein cDNA (AdGFP).
Two mouse pSM2 retroviral shRNAs for p53 and one retro-
viral scrambled shRNA construct were purchased from Open
Biosystems. The sense sequences of p53 shRNA were 5-ACC-
AGTCTACTTCCCGCCATAA-3 (RHS1764-9208347) and 5-
CCCACTACAAGTACATGTGTAA-3 (RMM1766-98468519).
Constructs were transfected into Phoenix-Eco cells for ret-
rovirus packaging and amplification using theMBSmamma-
lian transfection kit. Retrovirus containing supernatant was
used to infect VSMC, and transduced cells were selected
using puromycin (2.5 g/ml)-containing medium. Success-
ful suppression of p53 expression was confirmed byWestern
blot analysis.
Overexpression of PP1c1 Using the Adenoviral Infection
System—Adenoviral infection of nearly confluent VSMC was
performed at a multiplicity of infection of 100 in DMEM con-
taining 2%FBS.After 16 h of incubation, the cells were quiesced
in DMEM containing 0.1% FBS for 72 h.
Retroviral p53 andPp1c1 shRNAConstructs and Infection of
Mouse Aortic VSMC—Mouse retroviral shRNAmir against p53
and Pp1c1was purchased fromOpen Biosystems. The scram-
bled shRNA encoded a 19-bp scrambled sequence (5’-
GCGCGCTTTGTAGGATTCG)with no significant homology
to anymouse gene andwas cloned into pSUPER.retro.puro vec-
tor. Retroviral infection of VSMC was performed by spreading
3 ml of virus supplemented with 10 g/ml DEAE-dextran on
VSMC seeded in 100-mm plates. After 3 h of incubation, an
additional 7.0 ml of DMEM containing 10% FBS was added,
and the plates were incubated at 37 °C for 21 h. The infection
medium was then replaced with fresh DMEM containing
10% FBS. For p53 and Pp1c1 shRNA expression, puromy-
cin-resistant clones (selected with 2.5 g/ml puromycin for
10 days) were expanded prior to their use in experiments.
Cell ViabilityAssay—VSMCviability afterDMNQtreatment
was determined by either crystal violet staining or the trypan
blue exclusion method. In the former method, DMNQ-treated
VSMC in 96-well plates were washed with phosphate-buffered
saline and stained with 100 l of crystal violet solution (0.5%
(w/v) crystal violet, 1.5% (v/v) formaldehyde, and 1% (v/v) eth-
anol) for 30 min. After the wells were washed with water,
stained cells were lysed with 1% (w/v) deoxycholate solution,
and the absorbance was read at 560 nm using a microplate
reader. Trypan blue exclusion was determined microscopically
by scoring five fields of 100 cells each.
Intracellular ROS Measurement—VSMC (8  105) were
seeded in 24-well glass bottom plates, grown for 48 h in DMEM
containing 10% FBS, and quiesced for an additional 24 h in
culture medium containing 0.1% FBS. Cells were then treated
with Hanks’ balanced salt solution containing the H2O2-sensi-
tive fluorophore 2,7-dichlorofluorescin diacetate (5 M) for
30 min at 37 °C in darkness. The cells were treated with fresh
2,7-dichlorofluorescin diacetate and DMNQ and incubated
for another 30 min. For studying the effect of cellular oxidase
inhibitors on DMNQ-induced ROS production, VSMC were
pretreated with DPI, oxypurinol, proadifen, phenelzine,
indomethacin, or nordihydroguaiaretic acid for 30 min
before treatment with 2,7-dichlorofluorescein diacetate
and DMNQ. The fluorescence of DCF was measured using a
microplate reader at an excitation wavelength of 485 nm and
emission wavelength of 530 nm. Then cells were lysed, and
protein content was quantified.
Detection of Mitochondrial ROS—VSMC grown in glass bot-
tomdisheswere quiesced and treatedwith 10MDMNQ for 30
min. Cells were washed with Hanks’ balanced salt solution and
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incubated with 5 M MitoSOX Red and 1 M MitoTracker
Green FM (Molecular Probes) at 37 °C for 10min. Excess stains
were removed, and cells were imaged using Olympus FV500
confocal laser-scanning microscopy. MitoTracker Green FM
was visualized at an excitation of 490 nmand an emission of 516
nm, whereas MitoSOX Red was visualized at an excitation of
560 nm and an emission of 600 nm. MitoTracker Green FM
preferentially translocates to the mitochondria. MitoSOX Red
accumulates in mitochondria and exhibits bright red fluores-
cence upon oxidation and subsequent binding to mitochon-
drial DNA.
Detection of Changes in Mitochondrial Transmembrane
Potential—Changes in mitochondrial transmembrane poten-
tial were detected using the MitoCapture apoptosis detection
kit (BioVision Research Products), which provides a fluores-
cence-based method for distinguishing between healthy and
apoptotic cells. VSMC, either untreated or treated with 10 M
DMNQ for 15 h, were incubated with diluted MitoCapture
solution at 37 °C in a 5% CO2 incubator for 20 min. The cells
were washed with the incubation buffer three times and
mounted with Vectashield mounting medium (Vector Labora-
tories). Cells were photographed by fluorescent microscopy.
Isolation ofMitochondria—Mitochondria were isolated from
80% confluent VSMCusing a Piercemitochondrial isolation kit
according to the manufacturer’s instructions with the addition
of complete EDTA-free protease inhibitor mixture (Roche
Applied Science).
Western Blot Analysis—Cells were lysed in radioimmune
precipitation buffer (20 mM Tris-HCl, pH 7.6, 150 mM NaCl,
0.05mM sodium fluoride, 1mMEDTA, 1% Igepal, 0.05% sodium
deoxycholate, 0.1% SDS, and protease inhibitors), andWestern
analysiswas performed as described previously (30). Cell lysates
containing 50 g of protein were analyzed in Western blotting
experiments.
Assessment of Apoptosis—For detection of apoptosis,
growth-arrested VSMC were harvested after 16 h of treatment
with 10MDMNQ.Histone-associated DNA fragmentation in
cell lysates was determined using the cell death detection
ELISAPLUS kit (Roche Applied Science) in accordance with the
manufacturer’s instructions.
A TUNEL apoptosis detection kit (Upstate Biotechnology,
Inc.) was used tomeasure DNA fragmentation according to the
manufacturer’s protocol. Briefly, following treatment, the cells
were fixed in 4% paraformaldehyde and permeabilized by incu-
bating with 0.5% Tween 20 and 0.2% bovine serum albumin for
15min. Then cells were incubated with a reactionmix contain-
ing biotin-dUTP and terminal deoxynucleotidyltransferase for
60 min. Transfer of biotin-dUTP to the free 3-OH end of
cleaved DNA was visualized by reaction with fluorescein-con-
jugated avidin (fluorescein isothiocyanate-avidin) for 30 min
and photographed by fluorescence microscopy. Cells were
counterstained with propidium iodide.
Apoptosis was also assessed by measuring caspase-3/7 activ-
ities using an Apo-ONETM homogeneous caspase-3/7 assay kit
(Promega). Briefly, growth-arrested VSMC were treated with
10 M DMNQ for 6 h. The cells were lysed using bifunctional
cell lysis/activity buffer, which contained a profluorescent
caspase-3/7 consensus substrate, rhodamine 110 bis-N-benzyl-
oxycarbonyl-L-aspartyl-L-glutamyl-L-valyl-aspartic acid amide
(Z-DEVD-R110). After incubation at room temperature for 1 h,
aliquots (150 l) were transferred to a 96-well clear bottom
plate. Fluorescence was measured at an excitation wavelength
of 485 nm and an emissionwavelength of 535 nmusing aWAL-
LAC 1420 Multilabel Counter.
Measurement of Pp1c1 mRNA Expression—Total RNA
from VSMC that were either treated or untreated with DMNQ
was extracted using the RNeasy Micro kit (Qiagen). Reverse
transcription was performed with 1 g of total RNA using the
TaqMan reverse transcription reagents kit (Applied Biosys-
tems). The Pp1c1 gene expression assay (catalog number
Mm00849631-s1) was purchased from Applied Biosystems.
Real time PCR was performed using the ABI PRISM 7900 HT
Sequence Detection System and TaqMan PCR Master Mix
according to the manufacturer’s recommendations. Sequence
Detection System software (version 2.1) (Applied Biosystems)
was used for raw data analysis. Pp1c1 relative expression was
calculated using the Relative Expression Software Tool (31) and
by normalization to 18 S ribosomal expression.
Measurement of PP1c1Activity—PP1c1 activity wasmeas-
ured using the fluorescence-based RediPlate 96 EnzChek ser-
ine/threonine phosphatase assay kit from Molecular Probes.
VSMC were lysed in lysis buffer containing 20 mM Tris-Cl, pH
7.4, 132 mM NaCl, 10% glycerol, 1% Triton X-100, and a prote-
ase inhibitor mixture. Cell lysates containing 500 g of protein
were immunoprecipitated with anti-PP1c1 antibody over-
night at 4 °C and then incubated with Protein A-Sepharose
beads for another 2 h. The immunoprecipitates were washed
three times with lysis buffer and resuspended in 50 l of assay
buffer (50 mM Tris-Cl, pH 7.0, 0.1 mM CaCl2, 2 mM dithiothre-
itol, 200 M MnCl2, 125 g/ml bovine serum albumin, and
0.05% Tween 20) containing 50 M substrate, 6,8-difluoro-4-
methyl-umbelliferyl phosphate. The reaction was performed at
37 °C for 30 min in the dark. 6,8-Difluoro-4-methyl-umbel-
liferyl fluorescence was measured at an excitation wavelength
of 355 nm and an emission wavelength of 460 nm, using a
WALLAC 1420 multilabel counter. Phosphatase activity was
calculated using a 6,8-difluoro-4-methyl-umbelliferyl standard
curve.
Measurement of JNK1 Activity—JNK1 activity was assayed as
described elsewhere (32).
Statistical Analysis—All numerical data are expressed as
mean  S.E. Data were analyzed with one-way analysis of vari-
ance, and post hoc analysis was performed using the Newman-
Keuls test. Statistical significance was accepted at p  0.05.
RESULTS
Human Heart cDNA Library Screening—Genes that may
confer resistance to oxidative stress were identified by screen-
ing mouse aortic VSMC infected with a replication-deficient
retroviral cDNA library prepared from the human heart.
Freshly prepared virus was used for library screening so as to
ensure high transduction efficiency. The selection of an intra-
cellular oxidant that is highly apoptotic (close to 100% cell
death) is essential for efficient library expression screening for
VSMC clones with an oxidative stress-resistant phenotype and
for significantly decreasing false positives. In the present inves-
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tigation, mouse aortic VSMCwere incubated with apoptogenic
DMNQ (33, 34) for 16 h at increasing concentrations. 10–15
VSMC clones in a 150-mm dish resisted 60 M DMNQ.
Characterization of VSMC Clones Resistant to DMNQ-in-
duced Apoptosis—To identify cDNAs with an antiapoptotic
effect againstDMNQ, 1 107VSMCwere transducedwith 2
106 infectious units (2 times the size of the library) of retrovirus
containing a human heart cDNA library. This strategy ensured
that nearly the entire cDNA library is represented in the screen-
ing, and more than 90% of the transduced cells contained one
cDNA.
A total of 132 cell clones remained viable after treatment
with 60 MDMNQ and were able to form colonies on enriched
Glasgow modification of Eagle’s medium. No viable colonies
were recovered from the control-transduced cells. In order to
identify retrovirally introduced cDNAs responsible for the
DMNQ-resistant phenotype of VSMC clones, PCR analysis of
genomic DNA was performed using primers specific for the
retrovirus vector. We identified a total of 17 different full-
length cDNAs in DMNQ-resistant VSMC clones (Table 1).
Four of the 17 genes were previously shown to afford protec-
tion against oxidative stress, whereas the remaining genes were
not known tomodulate either apoptosis or oxidative stress. For
example, transcriptional down-regulation of aldolase and other
glycolytic enzymes was reported under oxidative stress condi-
tions (35). Further, increased expression of aldolase and
enhanced resistance to apoptosis were observed in cancer cell
lines with constitutive expression of HIF-1 (36). Although the
primary function of Myo (myoglobin) is cellular O2 storage, it
also acts as a ROS scavenger (37). Myo/ mouse hearts had
significantly higher levels of ROS than wild-type hearts under
ischemia/reperfusion conditions. Translationally controlled
tumor protein protects mammalian cells against chemically
induced apoptosis and cytotoxicity, and its overexpression
inhibited proapoptotic effector caspases (38). Similarly, overex-
pression of heat shock protein 27 (Hsp27) protects cisplatin-
induced apoptosis ofmouse fibroblasts (39) and human ovarian
tumor cells (40). Interestingly, plasma Hsp27 levels were
decreased in atherosclerotic patients compared with healthy
subjects (41), and down-regulation of this protein decreases
VSMC resistance to proteolytically induced apoptosis (42). We
chose to further investigate PP1c1, because it was the most
common cDNA expressed in VSMC resistant to DMNQ and
because inhibitors of PP1c1 are proapoptotic (18, 19), indicat-
ing a potential role for PP1c1 in protecting against apoptosis.
Verification of the Protective Effect of PP1c1 Overexpression
againstDMNQ—DMNQ-resistantVSMCcloneswere not pro-
duced when cells were exposed to 60 M DMNQ, suggesting
that spontaneous development of DMNQ resistance does not
occur in VSMC and is an unlikely explanation for DMNQ
resistance in PP1c1-overexpressing cells. However, it was
important to establish that PP1c1 overexpression in wild-type
VSMC could create DMNQ resistance. Cell viability was
reduced by 67 and 99% in adenoviral green fluorescent pro-
tein-expressing VSMC treated with 10 and 50 M DMNQ,
respectively. Adenoviral overexpression of PP1c1 increased
cell viability to 55 and 28% in VSMC treated with 10 and 50
M DMNQ (p  0.001 for each concentration compared with
adenoviral green fluorescent protein-expressing cells), respec-
tively (Fig. 1). These data suggest that PP1c1 cDNA originally
isolated from DMNQ-resistant VSMC clones was involved in
interrupting the DMNQ-induced apoptotic signaling pathways
in VSMC.
DMNQ Induces Mitochondrial ROS Production in VSMC—
Tocharacterize the protective effect ofPP1c1 againstDMNQ-
induced apoptosis in VSMC, we sought to determine the site of
DMNQ-induced intracellular ROS production. First, the effect
of DPI, an inhibitor of NADPH oxidase and other flavoprotein
FIGURE 1. Overexpression of PP1c1 increases VSMC viability after
DMNQ treatment. VSMC infected with AdGFP or AdPP1c1 were quiesced
for 3 days and treated with 10 or 50 M DMNQ or vehicle for 16 h. Cell viability
was determined by crystal violet staining. Data presented are mean  S.E. of
three independent experiments (* and **, p  0.001 compared with respec-
tive DMNQ-treated AdGFP VSMC).
TABLE 1
Genes representing full-length cDNAs isolated from DMNQ-resistant VSMC clones
Gene Accession number Function
N-Acetylglucosamine-1-phosphotransferase,  subunit, GNPTG NM_032520 Metabolism
Aldolase A, fructose-bisphosphate, transcript variant 1, ALDOA NM_000034.2 Metabolism
C9orf112 DR004665 Unclassified
Cardiac troponin I, type 3, TNNI3 NM_000363.4 Muscle and heart contraction
CDC42 effector protein 3, CDC42EP3 NM_006449.3 Cytoskeleton regulation
Coenzyme Q6 homolog monooxygenase, transcript variant 1, COQ6 NM_182476.1 Metabolism
Eukaryotic translation elongation factor 1 , transcript variant 2, EEF1D NM_001960.2 Translation
The 27-kDa heat shock protein 1, HSPB1 NM_001540 Stress resistance, antiapoptosis
Malate dehydrogenase, cytosolic,MDH1 NM_005917.2 Metabolism
MHC class I HLA-B,MHCI NM_005514.5 Immune response
MHC, class II, DM , HLA-DMA NM_006120.2 Immune response
Myoglobin, transcript variant 1,MB NM_005368.2 Oxygen transport, antiapoptosis
NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa, NDUFV2 NM_021074.2 Mitochondrial electron transport
Proteasome subunit,  type 1, PSMB1 NM_002793.2 Protein catabolism
Protein phosphatase I, catalytic subunit,  isoform, PP1CC NM_002710.1 Cell signaling
Translationally controlled tumor protein, TPT1 NM_003295.2 Antiapoptosis
Troponin T2, cardiac, transcript variant 3, TNNT2 NM_001001431.1 Muscle and heart contraction
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enzymes onDMNQ-induced ROS generationwas examined by
measuringDCF fluorescence. Comparedwith basal conditions,
10MDMNQ increasedROSproduction to about 1.8-fold (Fig.
2A). DPI (10 M) had no inhibitory effect on DMNQ-induced
ROS production in VSMC. In addition, no difference in DCF
fluorescence was observed between wild-type and p47phox-
deficient VSMC treated with DMNQ (data not shown). Next,
we examined the effects of other cellular oxidase inhibitors on
DMNQ-induced ROS production in VSMC. Oxypurinol (50
M), an inhibitor of xanthine oxidase; proadifen (30 M), an
inhibitor of cytochrome P450; phenelzine (10 M), an inhibitor
of monoamine oxidase; indomethacin (10 M), an inhibitor of
cyclooxygenase; or nordihydroguaiaretic acid (10 M), an
inhibitor of lipoxygenase, failed to significantly decrease
DMNQ-induced ROS production in VSMC.
To determine whether ROS production is enhanced inmito-
chondria of VSMC treated with DMNQ, we investigated the
colocalization of MitoTracker Green FM, a mitochondria-se-
lective dye, with MitoSOX Red, a superoxide-sensitive fluores-
cent dye (Fig. 3A). Compared with control cells, DMNQ-
treated VSMC showed bright yellow/orange fluorescence in
mitochondria, due to colocalization of MitoTracker Green and
MitoSOX Red, indicating increased mitochondrial ROS pro-
duction. To confirm DMNQ-induced increase in mitochon-
drial ROS production, VSMCwere pretreated with 20 M rote-
none, an inhibitor of complex I; 10M thenoyltrifluoroacetone,
            DPI                 -                     -                     +              




















DMNQ          -          +          +         +          +          +          +     
Oxypurinol          -           -          +          -          -           -           -     
Proadifen          -           -          -          +          -           -           -     
Phenelzine          -           -          -           -          +          -           -     
Indomethacin          -           -          -           -          -           +          -     






















FIGURE 2. DMNQ-induced ROS production is not attenuated by inhibitors
of endogenous oxidase systems. A, VSMC were pretreated with 10 M DPI
for 30 min and then treated with 10 M DMNQ for 2 h. ROS generation was
determined by measuring DCF fluorescence. Data presented are mean  S.E.
of three independent experiments (*, p  0.001 compared with control).
B, VSMC were pretreated with 50 M oxypurinol, 30 M proadifen, 10 M
phenelzine, 10 M indomethacin, or nordihydroguaiaretic acid for 30 min and
then treated with DMNQ for 2 h. Data presented are mean  S.E. of three
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FIGURE 3. DMNQ increases mitochondrial ROS production and disrupts
mitochondrial transmembrane potential in VSMC. A, confocal laser-scan-
ning microscopy showing colocalization of mitochondria-targeting fluores-
cent probe MitoSOX Red with the mitochondria-selective dye, MitoTracker
Green. Growth-arrested VSMC were treated with 10 M DMNQ for 30 min. The
yellow/orange fluorescence indicates localization of ROS in mitochondria.
B, growth-arrested VSMC were pretreated with 20 M rotenone, 10 M the-
noyltrifluoroacetone, or 2 M carbonyl cyanide m-chlorophenylhydrazone
for 30 min and then treated with 10 M DMNQ for 2 h. ROS generation was
determined by measuring DCF fluorescence. Data presented are mean  S.E.
of three independent experiments (*, p  0.001 compared with control).
C, growth-arrested VSMC were either left untreated (1 and 2) or treated with
10 M DMNQ for 16 h (3 and 4) and then incubated with diluted MitoCapture
solution for 20 min. Cells were washed with incubation buffer and visualized
using a fluorescent microscope. Mitochondrial membrane potential is indi-
cated by the red fluorescence of MitoCapture aggregated in the mitochon-
dria, and cells showing green fluorescence are apoptotic.
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an inhibitor of complex II; or 2 M carbonyl cyanidem-chloro-
phenylhydrazone, an uncoupler of oxidative phosphorylation,
and then treated with 10 MDMNQ for 2 h (Fig. 3B). All of the
mitochondrial electron transport chain inhibitors abrogated
the effect of DMNQ on ROS production, confirming enhanced
mitochondrial ROS generation in VSMC treated with DMNQ.
Together, these data indicate that increasedROSproduction by
DMNQ occurs predominantly in mitochondria of VSMC.
DMNQ Perturbs VSMC Mitochondrial Transmembrane
Potential, Leading toApoptosis—Enhancedmitochondrial ROS
production could result in the induction of potentially delete-
rious mitochondrial permeability transition, and perturbation
of mitochondrial transmembrane potential could lead to apo-
ptosis (43). Therefore, we measured changes in mitochondrial
transmembrane potential in VSMC treated with DMNQ, using
the MitoCapture apoptosis detection kit. MitoCapture is a cat-
ionic dye that aggregates in the mitochondria of healthy cells,
giving off a bright red fluorescence,whereas in apoptotic cells, it
remains in the cytoplasm in its monomeric form, fluorescing
green. The control cells showed only faint green fluorescence
but contained foci of red fluorescence in the cells (Fig. 3C).
DMNQ treatment for 15 h resulted in significant green fluores-
cence in the cytoplasm of VSMC and no red fluorescence, indi-
cating an increase in mitochondrial permeability. Together,
these data indicate that DMNQ induces VSMC apoptosis
through mitochondrial ROS-dependent mechanisms.
PP1c1 Activity Is Attenuated by DMNQ, Other Inducers of
Mitochondrial ROS, and H2O2—Because our data suggest that
overexpression of PP1c1 protects VSMC against DMNQ-in-
duced apoptosis, we investigated whether DMNQ treatment
inhibits the activity of PP1c1. Using immunoprecipitation and
a serine/threonine phosphatase assay kit from Molecular
Probes, an 22% decrease in PP1c1 activity (p  0.05 com-
pared with control) was observed at 2 h after treatment with 10
M DMNQ (Fig. 4A). PP1c1 activity decreased 75% at 8 h
(p  0.001 compared with control) after treatment with
DMNQ. Next, we investigated whether other agonists that
inducemitochondrial ROSproduction regulate PP1c1 activity
in VSMC. PP1c1 activity was significantly decreased in VSMC
at 4 and 0.5 h after treatment with 25 g/ml antimycin A and
100 ng/ml leptin, respectively (p  0.001) (Fig. 4, B and C). To
confirm that ROS regulate activity, PP1c1 immunoprecipi-
tated from VSMC lysates was incubated with 200 M H2O2.
The phosphatase activity was significantly inhibited 10 min
after incubation with H2O2 (p 0.001) and remained inhibited
during the 60-min incubation (Fig. 4D). Together, these data
indicate that increased mitochondrial ROS production inacti-
vates PP1c1 activity.
PP1c1 Is Abundant in VSMCMitochondria—The observa-
tion that PP1c1 activity is regulated by mitochondrial ROS-
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FIGURE 4. DMNQ, other inducers of mitochondrial ROS production, and
H2O2 decrease PP1c1 activity. Growth-arrested VSMC were treated with 10
M DMNQ (A), 25 g/ml antimycin A (B), or 100 ng/ml leptin (C) for the indicated
times, and cell lysates were immunoprecipitated with anti-PP1c1 antibody.
Phosphatase activity was measured using 6,8-difluoro-4-methyl-umbelliferyl
phosphate as substrate. Data presented are mean  S.E. (n  3) and repre-
sentative of three separate experiments (*, p  0.05; **, p  0.001 compared
with respective controls). D, PP1c1 was immunoprecipitated from VSMC
lysates containing equal amounts of protein, immobilized on protein A-aga-
rose beads, and incubated with 200 M H2O2 for the indicated times. Phos-
phatase activity was measured as described above, and data presented are
mean  S.E. (n  3) and representative of three separate experiments (*, p 
0.001 compared with control).
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dependent mechanisms raises the question of whether the
phosphatase is present in VSMC mitochondria. Western blot
analysis of subcellular fractions of VSMC homogenates dem-
onstrated that PP1c1 is present both in cytosol andmitochon-
dria, although it is more abundant in the latter (Fig. 5A).
DMNQ Attenuates VSMC PP1c1 Expression by Inducing
Proteasome-dependent Degradation—To further define the
inhibitory effect of DMNQ on PP1c1, we investigated the
steady-state protein levels of the phosphatase in VSMC by
Western blot analysis of cell lysates. DMNQ treatment for 8 h
decreased PP1c1 protein levels by 59% (p  0.001) (Fig. 5, B
and C). However, Pp1c1 mRNA levels in VMSC were unaf-
fected by DMNQ treatment, indicating that decreased protein
levels did not result from dysregulation of transcription (Fig.
5D). Next, we examined whether the low levels of PP1c1 pro-
tein in DMNQ-treated VSMC were caused by enhanced pro-
teasome-mediated degradation. Pretreatment of VSMC with
MG132, a proteasome inhibitor, partially but significantly (p 
0.001)attenuated theDMNQ-induceddecrease inPP1c1protein
levels after 8 h of treatment (Fig. 5, E and F). This was observed in
the absence of any change in Pp1c1 mRNA levels (data not
shown). Together, these data indicate that the DMNQ-induced
decrease in PP1c1 expression is, in part, mediated by the activa-
tion of the ubiquitin-proteasome pathway.
PP1c1 Overexpression Abrogates DMNQ-induced Cellular
Signaling Pathways—To explore the possible mechanisms by
whichPP1c1 overexpression attenuatesDMNQ-induced apo-
ptosis of VSMC, we examined the activity of stress-activated
protein kinase JNK1, expression of proapototic gene Bax, and
expression and phosphorylation of tumor suppressor gene p53.
A significant increase in JNK1 activity (p 0.001) was observed
using an immunocomplex kinase assay in control VSMC at 30
min after treatment with 10 MDMNQ (Fig. 5, A and B). JNK1
activity in response to DMNQ treatment was not significantly
different between control VSMC and cells infected with a con-
trol virus expressing enhanced green fluorescent protein
(AdGFP). However, adenoviral overexpression of PP1c1
(AdPP1c1) abrogated DMNQ-induced activation of JNK1 in
VSMC (Fig. 6, A and B). To determine whether the observed
regulatory effect of PP1c1 overexpression on JNK1 activity
was specific, we examined stimulation of ERK1/2 in VSMC
treated with DMNQ in the presence and absence of PP1c1
overexpression. ERK1/2 phosphorylation was significantly
enhanced in VSMC after DMNQ treatment (Fig. 6C), and
adenoviral overexpression of PP1c1 had no inhibitory effect
on DMNQ-induced ERK1/2 phosphorylation.
Western blot analysis of cell lysates using phosphospecific
antibody showed a significant increase in phosphorylation at
Ser15 of p53 in control VSMC (p  0.001) after a 2-h treatment
with DMNQ (Fig. 6, D (top) and E). Similarly, a significant
increase in p53 Ser15 phosphorylation (p  0.01) was observed
in AdGFP VSMC treated with DMNQ compared with
untreated AdGFP VSMC. Similar to its effect on JNK1, adeno-
viral overexpression of PP1c1 abrogated DMNQ-induced
phosphorylation of p53 (Ser15) in VSMC. Interestingly, control
and AdGFP VSMC tend to have higher p53 protein expression
levels after DMNQ treatment compared with their respective
untreated controls (Fig. 6, D (second panel) and F). However,
WB: PP1cγ1
WB: β-actin
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FIGURE 5. The subcellular localization and mechanism of expression of
PP1c1 in DMNQ-treated VSMC. A, VSMC homogenates and mitochondrial
and cytosolic fractions were analyzed by Western blotting (WB) with anti-
PP1c1 antibody, and the blot was reprobed with anti-cytochrome c (Cyt c)
antibody. B, growth-arrested VSMC were treated with 10 M DMNQ for the
indicated times, and the cell lysates were analyzed by Western blotting with
anti-PP1c1 antibody or anti--actin antibody. C, densitometric analysis of
PP1c1 protein levels (mean  S.E., n  3; *, p  0.001 compared with con-
trol). D, growth-arrested VSMC were treated with 10 M DMNQ for the indi-
cated times, and the relative expression of PP1c1 mRNA was assayed by real
time PCR. PP1c1 mRNA expression was normalized to 18 S rRNA (mean 
S.E., n  3). E, growth-arrested VSMC were pretreated with 5 M MG132 for 2 h
and then treated with DMNQ for the indicated times. Cell lysates were ana-
lyzed by Western blotting with anti-PP1c1 antibody or anti--actin anti-
body. F, densitometric analysis of PP1c1 protein levels (mean  S.E., n  3; *,
p  0.001 compared with the respective control).
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the increase in p53 protein expression in these two groups was
not statistically significant. The expression of p53 protein in
AdPP1c1 VSMC did not change after DMNQ treatment.
Because Bax expression is regulated by both JNK1 (44) and
p53 (45), we determined the effect of DMNQ on Bax levels in
VSMC. An10-fold increase in Bax protein level was observed
in VSMC treated with 10MDMNQ for 6 h (Fig. 6,G andH). A
similar increase in BAX expression
was observed inAdGFPVSMCafter
DMNQ treatment. However, PP1c1
overexpression completely inhib-
ited DMNQ-induced Bax protein
level in VSMC. Together, these data
indicate that high levels of PP1c1
protect VSMC against oxidative
stress-induced apoptosis by specifi-
cally interfering with JNK1 and p53
activation.
PP1c1 Activity and Expression
Regulate VSMC Apoptosis—Be-
cause suppression of PP1c1 activ-
ity and expression are correlated
with DMNQ-induced VSMC apop-
tosis and its overexpression in-
creases the viability of VSMC
treated with DMNQ, it is necessary
to determine the physiological
effect of suppression of endogenous
PP1c1 on VSMC survival. Okadaic
acid, a potent protein phosphatase
inhibitor, suppresses PP2A activity
at 20 nM, whereas it inhibits both
PP1 and PP2A activities at 100 nM
concentration (19). Treatment of
VSMCwith 100 nM okadaic acid for
12 h significantly increased histone-
associated DNA fragmentation in
VSMC (p  0.001 compared with
control), whereas 20 nM okadaic
acid had no such effect (Fig. 7A).
Further, okadaic acid had an addi-
tive effect on DMNQ-induced
VSMC apoptosis.
To complement the data indicat-
ing that the pharmacological inhib-
itor of PP1 activity induces apop-
tosis, we have used retroviral
expression ofPp1c1 shRNA to spe-
cifically silence the expression of
endogenous Pp1c1 in VSMC.
Infection of mouse aortic VSMC
with retroviral Pp1c1 shRNA con-
struct decreased PP1c1 expression
by 80% compared with cells
infected with retroviral scrambled
shRNA construct (Fig. 7B). Consist-
ent with induction of apoptosis by
okadaic acid, expression of Pp1c1
shRNA significantly enhanced histone-associated DNA frag-
mentation in VSMC compared with cells expressing scrambled
shRNA (Fig. 7C). Further, depletion of PP1c1 expression by
shRNA significantly enhanced DMNQ-induced VSMC apop-
tosis. In these experiments, we used DMNQ at a 5 M concen-
tration to better delineate the effect of suppression of endoge-
nous PP1c1 on oxidative stress-induced VSMC apoptosis.
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FIGURE 6. PP1c1 overexpression abrogates DMNQ-induced activation of JNK1, phosphorylation and
expression of p53, and expression of Bax in VSMC. A, control VSMC and VSMC infected with AdGFP or
AdPP1c1 were either untreated or treated with 10 M DMNQ for 30 min, and cell lysates containing equal
amounts of protein were immunoprecipitated with anti-JNK1 antibodies, and JNK1 activity was measured by
an immunocomplex kinase assay using glutathione S-transferase-c-Jun as a substrate (top). Aliquots of VSMC
lysates immunoprecipitated with anti-JNK1 antibodies were analyzed by Western blotting with anti-JNK1
antibody (bottom). B, densitometric analysis of JNK1 activity (glutathione S-transferase-c-Jun phosphoryla-
tion). Data presented are mean  S.E. (n  3; *, p  0.001 compared with their respective untreated cells).
C, control, AdGFP, and AdPP1c1 VSMC were either left untreated or treated with 10 M DMNQ for 10 min, and
cell lysates were analyzed by Western blotting with anti-phosphospecific ERK1/2, anti-ERK1/2, or anti-PP1c1
antibodies. D, control, AdGFP, and AdPP1c1 VSMC were treated with DMNQ for the indicated times, and cell
lysates were analyzed by Western blotting with anti-phosphospecific p53 (Ser15), anti-p53, anti--actin, or
anti-PP1c1 antibodies. E, densitometric analysis of p53 phosphorylation (mean  S.E., n  3; * and **, p 
0.001 and p  0.01, respectively, compared with their controls). F, densitometric analysis of p53 protein levels.
G, cell lysates from untreated and DMNQ-treated VSMC were analyzed by Western blotting with anti-Bax,
anti-PP1c1, or anti--actin antibodies. H, densitometric analysis of p53 protein levels (mean  S.E., n  3; *,
p  0.001 compared with untreated VSMC). IP, immunoprecipitation; WB, Western blot.
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PP1c1 Overexpression Attenuates DMNQ-induced VSMC
Apoptosis—Themorphological and cellular changes associated
with apoptosis are mediated by the activation of the caspase
cascade (46, 47). To determine whether overexpression of
PP1c1 attenuates apoptotic pathways, we examined DMNQ-
induced caspase-3/7 activities in VSMC infected with AdGFP
or AdPP1c1 constructs by measuring the release of the fluo-
rescent R110 group from the substrate, Z-DEVD-R110.
Although other caspases present in the whole cell lysates could
cleave this peptide, caspase-3 and -7 preferentially cleave
DEVD peptide from Z-DEVD-R110. Caspase-3/7 activity
increased5-fold (p 0.001) in AdGFPVSMC treatedwith 10
M DMNQ for 8 h (Fig. 7D). Adenoviral overexpression of
PP1c1 significantly attenuated (p  0.001) DMNQ-induced
caspase-3/7 activity in VSMC compared with that in DMNQ-
treated AdGFP VSMC (Fig. 7D).
Caspases function as effectors of apoptosis (48), and DNA
fragmentation as well as nuclear morphological changes occur
downstream of caspase activity (49, 50). An8-fold increase in
DNA fragmentation (p 0.001)was observed inAdGFPVSMC
after treatment with 10 M DMNQ (Fig. 7E). Adenoviral over-
expression of PP1c1 in VSMC significantly attenuated (p 
0.001) DMNQ-induced DNA fragmentation compared with
that in AdGFP VSMC treated with DMNQ (Fig. 7E). Together,
these data indicate that modulation of PP1c1 activity and
expression regulates VSMC viability.
Silencing of p53 Expression by shRNA Abrogates DMNQ-in-
duced Bax Protein Levels and Attenuates DMNQ-induced
Apoptosis in VSMC—To confirm the role of p53 in mediating
apoptosis induced by DMNQ through inhibition of PP1c1, we
have used retroviral expression of p53 shRNA to silence the
expression of the endogenous p53. Infection of mouse aortic
VSMC with retroviral p53 shRNA construct decreased p53
expression by85% compared with that in wild-type VSMC or
cells infected with retroviral scrambled shRNA construct (Fig.
8A).We next assessed the effect of expression of p53 shRNAon
Bax protein levels in VSMC treated with 10 MDMNQ for 6 h.
Expression of p53 shRNA abrogated DMNQ-induced increase
in Bax protein levels compared with that in cells expressing
scrambled shRNA (Fig. 8, B and C).
To determine if the observed abrogation of Bax expression in
response to DMNQ treatment in retroviral p53 shRNA-ex-
pressing cells resulted in decreased apoptosis, detection of
nucleosomes in cell lysates was performed. DMNQ-induced
DNA fragmentation was significantly decreased (p  0.001) in
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FIGURE 7. Inhibition of endogenous PP1c1 activity/expression induces
VSMC apoptosis, whereas its overexpression attenuates DMNQ-induced
caspase-3/7 activity and DNA fragmentation. A, VSMC were pretreated
with indicated concentrations of okadaic acid (OA) for 12 h and then treated
with 10 M DMNQ for 16 h. Cellular DNA fragmentation was measured using
the cell death detection ELISAPLUS kit (mean  S.E., n  3 and representative
of three separate experiments). B, VSMC stably expressing either retroviral
scrambled shRNA construct or retroviral PP1c1 shRNA construct were lysed,
and cell lysates were analyzed by either anti-PP1c1 or -actin antibody.
C, VSMC infected with scrambled shRNA or PP1c1 shRNA were either untreated
or treated with 5 M DMNQ for 16 h, and cell lysates were assayed for cellular
DNA fragmentation as described above. Data presented are mean  S.E.,
n  12 (*, p  0.001 compared with respective controls) and representative of
three separate experiments. D, VSMC infected with either AdGFP or
AdPP1c1 were either untreated or treated with 10 M DMNQ for 8 h and
were harvested in bifunctional cell lysis/activity buffer. The cell lysates were
incubated with caspase-3/7 consensus substrate, Z-DEVD-R110. The reaction
was measured at excitation and emission wavelengths of 485 and 535 nm,
respectively. Data presented are mean  S.E. (*, p  0.001 compared with
control; **, p  0.001 compared with DMNQ-treated AdGFP VSMC) of three
independent experiments. E, VSMC infected with either AdGFP or AdPP1c1
were either untreated or treated with DMNQ for 16 h, and cellular DNA frag-
mentation was measured (mean  S.E., n  3; *, p  0.001 compared with
control; **, p  0.001 compared with DMNQ-treated AdGFP VSMC) and are
representative of three separate experiments.
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expressing scrambled shRNA (Fig. 8D). Consistent with this,
VSMC infectedwith retroviral p53 shRNA showed low levels of
TUNEL-positive cells (Fig. 8E). In contrast, VSMC infected
with retroviral scrambled shRNA displayed highly elevated lev-
els of TUNEL-positive cells. Taken together, these results indi-
cate that PP1c1 expression regulates resistance to oxidant-
induced apoptosis in VSMC by modulating p53-dependent
cellular apoptotic pathways.
DISCUSSION
The present study was initiated to identify genes that impart
resistance to oxidative stress in VSMC. Using retrovirus-medi-
ated cDNA library expression screening, we identified PP1c1
and 16 other genes that protected VSMC against DMNQ tox-
icity. Our data illustrate that PP1c1 attenuates VSMC apopto-
sis by abrogating DMNQ-induced JNK1 activation, p53 phos-
phorylation, and Bax expression.
Activation of intracellular phosphorylation cascades leading
to stimulation of mitogen-activated protein kinases and p53
influences the survival of cells subjected to oxidant injury (51–
53). It is well established that inhibitors of PP1 or/and PP2A
induce apoptosis in several cell types (19, 54–57). Our results
demonstrate a significant decrease in PP1c1 activity and
expression in VSMC treated with DMNQ. We attribute the
decrease in PP1c1 activity to increased mitochondrial ROS
production upon DMNQ treatment. This observation is sup-
ported by our data indicating that PP1c1 activity is also
decreased in VSMC treated with antimycin and leptin, known
inducers ofmitochondrial ROS production (58, 59). The redox-
sensitive regulation of PP1c1 activity is also evident from sig-
nificant inhibition of its activity in the presence of H2O2 (Fig.
4D). It has been reported that other PP1 isoforms that possess
highly homologous catalytic domains to PP1c1 undergo reac-
tive site cysteine oxidation and inactivation by ROS (60).
Watanabe and Forman (5) reported that autoxidation of hyd-
roquinone formed from two-electron reduction of DMNQ by
NAD(P)H quinone oxidoreductase 1 yields most of the ROS
generated in cells treatedwith low concentrations ofDMNQ. In
the present study, we did not observe any inhibition of DMNQ-
induced ROS production in VSMC by inhibitors of various cel-
lular oxidases (Fig. 2). In contrast, all electron transport chain
inhibitors attenuated DMNQ-induced ROS production in
VSMC, indicating enhanced mitochondrial ROS generation
upon DMNQ treatment. Further support for increased mito-
chondrial ROS generation is evident from the bright yellow/
orange fluorescence resulting from colocalization of Mito-
Tracker Green and MitoSOX Red in the mitochondria of
VSMC treated with DMNQ. Therefore, ROS production
occurs predominantly in mitochondria of VSMC treated with
DMNQ. Similarly, an increase in mitochondrial ROS genera-
tion was observed in pancreatic acinar cells treated with men-
adione, another naphthoquinone (61). However, redox cycling
of DMNQmight induce ROS production in the cytosol (5). The
presence of PP1c1 in both the cytosol and mitochondria (Fig.
5A) makes it a target of increased ROS levels in the cytosol and
mitochondria of VSMC treated with DMNQ.
In addition to decreasing activity, DMNQ also decreased
PP1c1 protein levels in VSMC. However, the decrease in
PP1c1 protein levels did not result from decreased mRNA
levels. Although the decrease in protein levels could result from
decreased translation of mRNA, our data indicate that protea-
some-mediated degradation partially contributes to lower
PP1c1 levels observed at 8 h after DMNQ treatment. The abil-
ity of DMNQ to induce proteasome-dependent degradation of
proteins has been reported recently (62).
The activation of caspases is a central step in the apoptosis
signaling cascade, and caspases transduce regulatory upstream
signals into the cell death execution machinery (46). Jänicke et
al. (49) demonstrated that caspase-3 is required for DNA frag-
mentation that accompanies apoptosis. Caspase-3 activates an
endonuclease, CAD, responsible for fragmentation of the DNA
at the linker region between nucleosomes, by inactivating
ICAD (DEF45), the inhibitor of CAD (50, 63). Consistent with
previous observations (34, 61), DMNQ at a 10 M concentra-
tion caused significant increases in caspase-3/7 activity and
DNA fragmentation at 8 and 16 h after treatment. Caspase-3
was shown to disrupt the functions of complex I and II of the
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FIGURE 8. p53 shRNA abrogates Bax expression and attenuates apoptosis
in VSMC treated with DMNQ. A, VSMC stably expressing either retroviral
scrambled shRNA construct or retroviral p53 shRNA construct were lysed, and
cell lysates were analyzed by either anti-p53 or -actin antibody. B, VSMC
expressing retroviral scrambled RNA or retroviral p53 shRNA constructs were
either left untreated or treated with 10 M DMNQ for 6 h, and cell lysates were
analyzed by Western blotting with either anti-Bax antibody or -actin anti-
body. C, densitometric analysis of Bax protein levels. Data presented are
mean  S.E. (*, p  0.01 compared with control) of three independent exper-
iments. D, VSMC infected with either retroviral scrambled shRNA or retroviral
p53 shRNA were either left untreated or treated with DMNQ for 16 h, and
cellular DNA fragmentation was measured using the cell death detection
ELISAPLUS kit. Data presented are mean  S.E. (n  3; *, p  0.001 compared
with control; **, p  0.001 compared with DMNQ-treated retroviral scram-
bled RNA expressing VSMC) and are representative of three separate experi-
ments. E, VSMC infected with either retroviral scrambled RNA or retroviral p53
shRNA were either left untreated or treated with 10 M DMNQ for 16 h, and
apoptosis was detected by TUNEL staining (green fluorescence). Cells were
counterstained with propidium iodide.
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transmembrane potential and generation of ROS (64). Indeed,
we observed a significant decrease inmitochondrial transmem-
brane potential of VSMC treated with DMNQ.
Amajor conclusion of our study is that PP1c1 has a prosur-
vival function in the response of VSMC to oxidative stress, and
a decrease in its activity and expression results in apoptosis.
This notion is supported by our observation that okadaic acid,
at a concentration (100 nM) known to inhibit PP1 activity, sig-
nificantly increased VSMC apoptosis. Further, DMNQ exerted
an additive effect on VSMC apoptosis in the presence of oka-
daic acid. Importantly, suppression of PP1c1 expression sig-
nificantly enhanced basal as well as DMNQ-induced apoptosis
in VSMC. Then how could PP1c1 overexpression protect
VSMC against DMNQ-induced oxidative stress?
One putative mechanism for increased survival of DMNQ-
treated VSMC overexpressing PP1c1 could be interruption of
the JNK1 cascade. JNK1 activation has been implicated in apo-
ptosis (24) and was shown to be necessary for the release of
cytochrome c from the mitochondria (26). Further, JNK1 is
upstream of caspase-3 activation in apoptosis induced by sev-
eral stressors (65, 66). Consistent with the observation of Ram-
achandran et al. (34), a significant increase in JNK1 activity was
observed inDMNQ-treatedVSMC in the present investigation.
However, PP1c1 overexpression abrogated DMNQ-induced
JNK1 activity. This finding is supported by a recent report that
inhibition of PP1 leads to phosphorylation and activation of
JNK1 in cancer cells, and PP1 directly inactivates JNK1 in vitro
(67). It is noteworthy that suppression of JNK1 provides signif-
icant protection against apoptosis (25).
JNK1 is known to phosphorylate p53, resulting in p53 accu-
mulation and activation as a transcriptional regulator (68, 69).
p53, a master regulator of apoptosis, regulates cell death by two
mechanisms: 1) by transcriptional regulation of expression of
genes involved in apoptosis (70, 71); 2) by activation of Bax in
mitochondria to antagonize Bcl-2 and Bcl-XL, the antiapopto-
tic genes (72). The transcriptional activity of p53 is regulated
by several post-translational mechanisms, including phos-
phorylation/dephosphorylation, acetylation/deacetylation,
ubiquitylation, sumoylation, and glycosylation (23, 73, 74).
Phosphorylation and dephosphorylation impact both stability
and function of p53 (73, 74). Consistent with DMNQ-induced
apoptosis, we observed increased phosphorylation of p53 at
Ser15 in DMNQ-treated VSMC lysates. The increase in p53
Ser15 phosphorylation was abrogated by overexpression of
PP1c1. These results are supported by an observation that PP1
dephosphorylates p53 at Ser15 and Ser37 in in vitro and in vivo
dephosphorylation assays, and PP1 promotes cell survival by
negatively regulating the p53-dependent death pathway (23).
Consistent with the report of Sandau et al. (37), we observed
increased Bax expression in VSMC treated with DMNQ. p53
was shown to up-regulate Bax expression by binding to the
regulatory region of the gene (45). Alternatively, JNK can
enhance the expression of Bax by either increasing AP-1 activ-
ity (75) or stabilizing the protein (44). Bax is located in the
cytosol but inserts into mitochondrial membrane after an apo-
ptotic signal (76). Again, JNK can promote the translocation of
Bax to mitochondria through phosphorylation of 14-3-3 pro-
tein, a cytoplasmic anchor of Bax (77). It has been suggested
that mitochondrial Bax associates with components of the
mitochondrial permeability transition pore to cause loss of
mitochondrial membrane potential. In fact, Bax translocation
from the cytosol to the mitochondria was observed during
DMNQ-induced apoptosis (78). Complementary to the reports
that inhibition of PP1 induces the expression of p53 and Bax
(19), PP1c1 overexpression abrogated DMNQ-induced Bax
expression in VSMC. Consistent with this, PP1c1 overexpres-
sion attenuatedDMNQ-induced caspase-3/7 activity andDNA
fragmentation in VSMC. Further, p53 shRNA abrogated
DMNQ-induced Bax expression and attenuated DMNQ-in-
duced apoptosis, confirming that PP1c1 negatively regulates
VSMC apoptosis cascades bymodulating p53 phosphorylation.
In conclusion, our results demonstrate that PP1c1 attenu-
ates DMNQ-inducedVSMC apoptosis by abrogating JNK1 and
p53 Ser15 phosphorylation. It is possible that dephosphoryla-
tion of other phosphoproteins by PP1c1 might play a role in
the survival of VSMC under oxidative stress conditions. This
finding supports further investigation of PP1c1 expression in
restenosis and atherosclerosis, since VSMC apoptosis pro-
foundly affects these arterial diseases.
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